Mumbai, August 04, 2018: Aurobindo Pharma said on 5 June it has received approval from the US Food and Drug Administration (USFDA) for its antibiotic drug Cefpodoxime proxetil in multiple strengths.
This is the sixth such approval for the company, with which it has representation in each of the first three generations of cephalosporin antibiotics, Aurobindo Pharma said in a communique to the Bombay Stock Exchange (BSE).
The approval is for Cefpodoxime proxetil in the strengths of 50mg/5ml and 100mg/5ml.
Cefpodoxime is the generic version of Pharmacia Upjohn’s Vantin. The drug is used to treat acute otitis media, community acquired Pneumonia, urinary tract infections and skin infections according to the reports published in livemint.com.
This would be an interesting niche opportunity for the company as there are limited number of players in the segment, Aurobindo Pharma added.
The shares of the company were trading at Rs729.40, up 1.31% on the BSE.
